PUBLIC COMPANY
save$IRDOpus Genetics, Inc.
$IRD2.9200-4.26%Durham, NC, USupdated 3mo ago
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
3Preclinical1Phase 21Phase 31Marketed
Marketed
phentolamine mesylate
Presbyopia
Adrenergic receptor alpha
Phase 3OPGx-LCA5
Leber Congenital Amaurosis (LCA)
Phase 2OPGx-BEST1
Macular Degeneration
PreclinicalOPGx-CNGB1
Retinitis Pigmentosa (Retinitis)
PreclinicalOPGx-RDH12
Leber Congenital Amaurosis (LCA)
PreclinicalOPGx-RHO
Retinitis Pigmentosa (Retinitis)
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
- phase2Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
- phase3Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
- phase2Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
- phase3OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
- phase2Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
- phase2Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
🐶 Hiring Signal
News
- FDA considers interim access for compounded peptides; Enspryng's label expansionPlus news about Microbiotica, Cyrano Therapeutics and Opus Genetics. HHS and FDA submit peptide policy for review: An “interim access policy for compounding using certain peptides” is awaiting regu…endpoints · 1mo ago
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that